126 related articles for article (PubMed ID: 15258678)
41. New hormonal contraceptives: a comprehensive review of the literature.
Forinash AB; Evans SL
Pharmacotherapy; 2003 Dec; 23(12):1573-91. PubMed ID: 14695038
[TBL] [Abstract][Full Text] [Related]
42. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
43. Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy.
Crosignani PG; Nappi C; Ronsini S; Bruni V; Marelli S; Sonnino D;
BMC Womens Health; 2009 Jun; 9():18. PubMed ID: 19566925
[TBL] [Abstract][Full Text] [Related]
44. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Kaunitz AM; Archer DF; Mishell DR; Foegh M
Am J Obstet Gynecol; 2015 Mar; 212(3):318.e1-8. PubMed ID: 25220709
[TBL] [Abstract][Full Text] [Related]
45. A clinical study of transdermal contraceptive patch in Thai women.
Suwanmalee O; Taneepanichskul S
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S1-4. PubMed ID: 17726805
[TBL] [Abstract][Full Text] [Related]
46. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick S; Kaye JA; Li L; Jick H
Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
[TBL] [Abstract][Full Text] [Related]
47. Norelgestromin/ethinyl estradiol transdermal system.
Taneepanichskul S
J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S82-4. PubMed ID: 17722322
[TBL] [Abstract][Full Text] [Related]
48. Comparing patient telephone callback rates for different hormonal birth control delivery systems.
Victor I; Fink RA
Am J Ther; 2006; 13(6):507-12. PubMed ID: 17122531
[TBL] [Abstract][Full Text] [Related]
49. Suppression of estrogen-withdrawal headache with extended transdermal contraception.
LaGuardia KD; Fisher AC; Bainbridge JD; LoCoco JM; Friedman AJ
Fertil Steril; 2005 Jun; 83(6):1875-7. PubMed ID: 15950671
[TBL] [Abstract][Full Text] [Related]
50. Contraceptive patch and vaginal ring vs. combined oral contraceptives.
Meyer S
Am Fam Physician; 2009 Aug; 80(3):232. PubMed ID: 19621832
[No Abstract] [Full Text] [Related]
51. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study.
Piltonen T; Puurunen J; Hedberg P; Ruokonen A; Mutt SJ; Herzig KH; Nissinen A; Morin-Papunen L; Tapanainen JS
Hum Reprod; 2012 Oct; 27(10):3046-56. PubMed ID: 22811306
[TBL] [Abstract][Full Text] [Related]
52. Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants.
Abrams LS; Skee DM; Natarajan J; Wong FA; Lasseter KC
Contraception; 2001 Nov; 64(5):287-94. PubMed ID: 11777488
[TBL] [Abstract][Full Text] [Related]
53. The transdermal contraceptive system.
Burkman RT
Am J Obstet Gynecol; 2004 Apr; 190(4 Suppl):S49-53. PubMed ID: 15105798
[TBL] [Abstract][Full Text] [Related]
54. How should we advise patients about the contraceptive patch, given the FDA warning?
Thacker HL; Falcone T; Atreja A; Jain A; Harris CM
Cleve Clin J Med; 2006 Jan; 73(1):45-7. PubMed ID: 16444915
[No Abstract] [Full Text] [Related]
55. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
Merz M; Kroll R; Lynen R; Bangerter K
Contraception; 2015 Feb; 91(2):113-20. PubMed ID: 25453585
[TBL] [Abstract][Full Text] [Related]
56. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses.
Lindberg M; Foldemo A; Josefsson A; Wiréhn AB
Eur J Contracept Reprod Health Care; 2012 Apr; 17(2):106-18. PubMed ID: 22385398
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial.
Audet MC; Moreau M; Koltun WD; Waldbaum AS; Shangold G; Fisher AC; Creasy GW;
JAMA; 2001 May; 285(18):2347-54. PubMed ID: 11343482
[TBL] [Abstract][Full Text] [Related]
58. Adolescents' experiences using the contraceptive patch versus pills.
Sucato GS; Land SR; Murray PJ; Cecchini R; Gold MA
J Pediatr Adolesc Gynecol; 2011 Aug; 24(4):197-203. PubMed ID: 21454110
[TBL] [Abstract][Full Text] [Related]
59. Evra contraceptive patch: risks of thromboembolism.
Prescrire Int; 2007 Jun; 16(89):113-4. PubMed ID: 17590909
[No Abstract] [Full Text] [Related]
60. Transdermal hormonal contraception: benefits and risks.
Burkman RT
Am J Obstet Gynecol; 2007 Aug; 197(2):134.e1-6. PubMed ID: 17689623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
